Neuroleptic-induced catatonia: Clinical presentation, response to benzodiazepines, and relationship to neuroleptic malignant syndrome

Journal of Clinical Psychopharmacology

Volumn 30, Issue 1, 2010, Pages 3-10

  Lee, Joseph W Y ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Benzodiazepines; Catatonia; Extrapyramidal reactions; Neuroleptic malignant syndrome; Neuroleptic induced catatonia

Indexed keywords

BENZATROPINE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CLONAZEPAM; DIAZEPAM; FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; HALOPERIDOL; LITHIUM CARBONATE; LORAZEPAM; RISPERIDONE; THIORIDAZINE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL DECANOATE;

ADOLESCENT; ADULT; AGED; ARTICLE; BIPOLAR MANIA; CATATONIA; CLINICAL FEATURE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DELIRIUM; DEMENTIA; EPILEPSY; FEMALE; FEVER; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MANIA; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSONISM; PRIORITY JOURNAL; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CATATONIA; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME; PROSPECTIVE STUDIES;

EID: 74549124287     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181c9bfe6     Document Type: Article

References (56)

1. Taylor MA. Catatonia: a review of a behavioral neurologic syndrome. Neuropsychiatry Neuropsychol Behav Neurol. 1990;3:48-72.
2. Lopez-Canino A, Francis A. Drug-induced catatonia. In: Caroff SN, Mann SC, Francis A, et al, eds. Catatonia: From Psychopathology to Neurobiology. Washington DC: American Psychiatric Publishing; 2004:129-139.
3. Berry RV, Kamin SH, Kline A. An unusual complication following the use of trilafon in children. U S Armed Forces Med J. 1958;9: 745-749.
4. May RH. Catatonic-like states following phenothiazine therapy. Am J Psychiatry. 1959;115:1119-1120.
5. Behrman S. Mutism induced by phenothiazines. Br J Psychiatry. 1972;121:599-604.
6. De UJ. Catatonia from fluphenazine. Br J Psychiatry. 1973;122:240-241.
7. Gelenberg AJ, Mandel MR. Catatonic reactions to high-potency neuroleptic drugs. Arch Gen Psychiatry. 1977;34:947-950.
8. Ungvari G, Petho B. Reversal of neuroleptic-induced stupor by procyclidine: two case reports and their theoretical implications. Pharmakopsychiatr Neuropsychopharmakol. 1979;12:257-260.
9. Cremona-Barbaro A. Neuroleptic-induced catatonic symptoms. Br J Psychiatry. 1983;142:98-99.
10. Johnson GC, Manning DE. Neuroleptic-induced catatonia: case report. J Clin Psychiatry. 1983;44:310-312.
11. Dorevitch A, Gabbay F. Neuroleptic-associated catatonic reaction. Clin Pharm. 1983;2:581-582.
12. Fricchione GL, Cassem NH, Hooberman D, et al. Intravenous lorazepam in neuroleptic-induced catatonia. J Clin Psychopharmacol. 1983;3:338-342.
13. Stoudemire A, Luther JS. Neuroleptic malignant syndrome and neuroleptic-induced catatonia: differential diagnosis and treatment. Int J Psychiatry Med. 1984;14:57-63.
14. Mayer C. Mental handicap, psychosis and thyrotoxicosis: a demonstration of the usefulness of an integrated community and hospital service. J Ment Defic Res. 1985;29:275-280.
15. Brown CS, Wittkowsky AK, Bryant SG. Neuroleptic-induced catatonia after abrupt withdrawal of amantadine during neuroleptic therapy. Pharmacotherapy. 1986;6:193-195.
16. Hoffman AS. Catatonic reaction to accidental haloperidol overdose: an unrecognized drug abuse risk. J Nerv Ment Dis. 1986;174: 428-430.
17. Herrmann N, Lieff SJ. Drug-induced catatonia. Can J Psychiatry. 1988;33(7):633-634.
18. de Leon J, Saiz-Ruiz J, Alonso-Abolafia A, et al. Neuroleptic-induced catatonia: neuroleptic malignant syndrome? Prog Neuropsychopharmacol Biol Psychiatry. 1990;14:129-136.
19. Kontaxakis VP, Vaidakis NM, Christodoulou GN, et al. Neuroleptic-induced catatonia or a mild form of neuroleptic malignant syndrome? Neuropsychobiology. 1990;23:38-40.
20. Woodbury MM, Woodbury MA. Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry. 1992;31:1161-1164.
21. Dose M. Recognition and management of acute neuroleptic-induced extrapyramidal motor and mental syndromes. Pharmacopsychiatry. 2000;33(suppl):3-13.
22. Dose M. Neuroleptic-induced pseudo-catatonia. Pharmacopsychiatry. 2001;34:262-264.
23. Chakraborty N, Johnston T. Aripiprazole and neuroleptic malignant syndrome. Int Clin Psychopharmacol. 2004;19:351-353.
24. Tsai JH, Yang P, Yen JY, et al. Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome. Pharmacotherapy. 2005;25:1156-1159.
25. Caroff SN. The neuroleptic malignant syndrome. J Clin Psychiatry. 1980;41:79-83.
26. Bahro M, Kampf C, Strnad J. Catatonia under medication with risperidone in a 61-year-old patient. Acta Psychiatr Scand. 1999;99:223-224.
27. Kanes SJ, Hitzemann BA, Hitzemann RJ. On the relationship between D2 receptor density and neuroleptic-induced catalepsy among eight inbred strains of mice. J Pharmacol Exp Ther. 1993; 267:538-547.
28. Lohr JB, Wisenewski AA. Catalepsy. In: Movement DisordersVA Neuropsychiatric Approach. New York, NY: Guilford Press; 1987:138-142.
29. Thornton A, McKenna PJ. Acute dystonic reactions complicated by psychotic phenomena. Br J Psychiatry. 1994;164:115-118.
30. Riley T, Brannon WJ Jr, Davis W. Phenothiazine reaction simulating acute catatonia. Postgrad Med. 1976;60:171-173.
31. Bush G, Fink M, Petrides G, et al. Catatonia II. Treatment with lorazepam and electroconvulsive therapy. Acta Psychiatr Scand. 1996;38:137-143.
32. Lee JWY, Schwartz DL, Hallmayer J. Catatonia in a psychiatric intensive care facility: incidence, and response to benzodiazapines. Ann Clin Psychiatry. 2000;12:89-96.
33. Deniker P. Experimental neurological syndromes and the new drug therapies in psychiatry. Compr Psychiatry. 1960;1:92-102.
34. White AC, Robins AH. Catatonia: harbinger of the neuroleptic malignant syndrome. Br J Psychiatry. 1991;158:419-421.
35. White AC, Robins AH. Catatonia and neuroleptic malignant syndrome Br J Psychiatry. 1991;158:858-859.
36. Paparrigopoulos T, Tzavellas E, Ferentinos P, et al. Catatonia as a risk factor for the development of neuroleptic malignant syndrome: report of a case following treatment with clozapine. World J Biol Psychiatry. 2009;10:70-73.
37. Singerman B, Raheja R. Malignant catatoniaVa continuing reality. Ann Clin Psychiatry. 1994;6:259-266.
38. Mann SC, Caroff SN, Bleier HR, et al. Lethal catatonia. Am J Psychiatry. 1986;143:1374-1381.
39. Hynes AF, Vickar EL. Case study: neuroleptic malignant syndrome without pyrexia. J Am Acad Child Adolesc Psychiatry. 1996;35:959-962.
40. Fink M. Recognising NMS as a type of catatonia. Neuropsychiatry Neuropsychol Behav Neurol. 1995;8:75-76.
41. Lee JWY. Catatonic and non-catatonic neuroleptic malignant syndrome. Aust N Z J Psychiatry. 2000;34:877.
42. Lee JWY. Catatonic variants, hyperthermic extrapyramidal reactions, and subtypes of neuroleptic malignant syndrome. Ann Clin Psychiatry. 2007;19:9-16.
43. Rosebush PI, Hildebrand AM, Furlong BG, et al. Catatonic syndrome in a general hospital psychiatric population: frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry. 1990;51:357-362.
44. Bush G, Fink M, Petride G, et al. Catatonia I. Rating scale and standardized examination. Acta Psychiatr Scand. 1996;93: 129-136.
45. Lee JWY. Serum iron in catatonia and neuroleptic malignant syndrome. Biol Psychiatry. 1998;44:499-507.
46. Fink M, Taylor MA. Catatonia: A Clinician-s Guide to Diagnosis and Treatment. Cambridge, UK: Cambridge University Press; 2003.
47. Pope HG, Keck PE, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry. 1986;143:1227-1233.
48. Lee JWY. Laboratory findings. In: Caroff SN, Mann SC, Francis A, et al, eds. Catatonia: From Psychopathology to Neurobiology. Arlington, VA: American Psychiatric Publishing; 2004.
49. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985;142:1137-1145.
50. Mann SC, Caroff SN, Keck P Jr, et al. Neuroleptic Malignant Syndrome and Related Conditions. Washington DC: American Psychiatric Publishing; 2003.
51. Caroff SN, Mann SC, Francis A, et al. Catatonia: From Psychopathology to Neurobiology. Arlington, VA: American Psychiatric Publishing; 2004.
52. Rogers D. Motor Disorder in Psychiatry: Towards a Neurological Psychiatry. Chichester, NY: J Wiley & Sons; 1992.
53. Tonda ME, Guthrie SK. Treatment of acute neuroleptic-induced movement disorders. Pharmacotherapy. 1994;14:543-560.
54. Borison RL. Amantadine in the management of extrapyramidal side effects. Clin Neuropharmacol. 1983;6(suppl 1):S57-S63.
55. Northoff G, Eckert J, Fritze J. Glutamatergic dysfunction in catatonia? Successful treatment of three acute akinetic catatonic patients with the NMDA antagonist amantadine. J Neurol Neurosurg Psychiatry. 1997;62:404-406.
56. Carroll BT, Goforth HW, Thomas C, et al. Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes. J Neuropsychiatry Clin Neurosci. 2007;19:406-412.